R&D | March 19, 2026
IIT Roorkee unveils cutting-edge molecular medicine facility
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Giredestrant shows promise despite missing primary goal
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
